[{"address1": "455 Mission Bay Boulevard South", "city": "San Francisco", "state": "CA", "zip": "94158", "country": "United States", "phone": "415 482 5300", "fax": "415 339 5300", "website": "https://www.nektar.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.", "fullTimeEmployees": 137, "companyOfficers": [{"maxAge": 1, "name": "Mr. Howard W. Robin", "age": 70, "title": "CEO, President & Director", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 2208416, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sandra A. Gardiner", "age": 57, "title": "Interim Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 376300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark A. Wilson", "age": 51, "title": "Senior VP, Chief Legal Officer & Secretary", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 868678, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jonathan  Zalevsky Ph.D.", "age": 48, "title": "Chief Research & Development Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 1595064, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Vivian  Wu", "title": "Director of Investor Relations & Corporate Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Bacci", "title": "Senior Vice President of Human Resources & Facilities Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Ruddock", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mary  Tagliaferri L.Ac., M.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 2, "overallRisk": 6, "governanceEpochDate": 1716940800, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://ir.nektar.com/", "maxAge": 86400, "priceHint": 4, "previousClose": 1.38, "open": 1.37, "dayLow": 1.22, "dayHigh": 1.4002, "regularMarketPreviousClose": 1.38, "regularMarketOpen": 1.37, "regularMarketDayLow": 1.22, "regularMarketDayHigh": 1.4002, "beta": 0.71, "forwardPE": -1.826087, "volume": 2994910, "regularMarketVolume": 2994910, "averageVolume": 2617885, "averageVolume10days": 1717500, "averageDailyVolume10Day": 1717500, "bid": 1.23, "ask": 1.28, "bidSize": 200, "askSize": 1000, "marketCap": 231865200, "fiftyTwoWeekLow": 0.41, "fiftyTwoWeekHigh": 1.93, "priceToSalesTrailing12Months": 2.5715084, "fiftyDayAverage": 1.4046, "twoHundredDayAverage": 0.7994, "currency": "USD", "enterpriseValue": 174064016, "profitMargins": -1.95016, "floatShares": 163181691, "sharesOutstanding": 184020000, "sharesShort": 2647761, "sharesShortPriorMonth": 3113324, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.014400001, "heldPercentInsiders": 0.01086, "heldPercentInstitutions": 0.6188, "shortRatio": 1.41, "shortPercentOfFloat": 0.0185, "impliedSharesOutstanding": 199655008, "bookValue": 0.69, "priceToBook": 1.826087, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -175840000, "trailingEps": -0.91, "forwardEps": -0.69, "pegRatio": 0.28, "lastSplitFactor": "2:1", "lastSplitDate": 966988800, "enterpriseToRevenue": 1.93, "enterpriseToEbitda": -1.387, "52WeekChange": 1.032258, "SandP52WeekChange": 0.22256601, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "NKTR", "underlyingSymbol": "NKTR", "shortName": "Nektar Therapeutics", "longName": "Nektar Therapeutics", "firstTradeDateEpochUtc": 767971800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "416283a3-1f17-365e-abc6-f451db95daa1", "messageBoardId": "finmb_29929", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.26, "targetHighPrice": 1.6, "targetLowPrice": 1.6, "targetMeanPrice": 1.6, "targetMedianPrice": 1.6, "recommendationMean": 3.2, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 289238016, "totalCashPerShare": 1.575, "ebitda": -125541000, "totalDebt": 231935008, "quickRatio": 5.623, "currentRatio": 6.103, "totalRevenue": 90167000, "debtToEquity": 183.051, "revenuePerShare": 0.471, "returnOnAssets": -0.17313999, "returnOnEquity": -0.95677, "freeCashflow": -66601376, "operatingCashflow": -188579008, "revenueGrowth": 0.002, "grossMargins": 0.60915, "ebitdaMargins": -1.3923199, "operatingMargins": -1.59213, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-31"}]